KalVista Pharmaceuticals, Inc. (KALV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.000.00%
Close 2026-06-12 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KALV
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 | Apr 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | — | — | — | — | — | — | 12.7 | 16.1 | 8.4 | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | 8.4 | — | — |
| Operating Expenses & Income | |||||||||||
| R&D Expenses | — | 71.7 | 86.2 | 80.3 | 70.2 | 41.3 | 40.2 | 35.0 | 18.2 | 12.7 | 16.2 |
| Operating Income | — | (188.0) | (140.4) | (110.9) | (96.6) | (57.9) | (40.5) | (29.8) | (18.7) | (22.3) | (21.0) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | 5.8 | — | — | — | — | — | — | — | — | 1.2 |
| Interest & Investment Income | — | 6.4 | 3.9 | 2.2 | 1.1 | 0.9 | 1.8 | 1.4 | 0.1 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | 1.2 |
| Other Non-Operating Income / Expenses | — | 7.9 | 13.8 | 18.0 | 14.3 | 11.7 | 11.3 | 9.1 | 2.9 | 3.7 | (3.8) |
| EBT, Incl. Unusual Items | — | (180.1) | (126.6) | (92.9) | (82.3) | (46.2) | (29.2) | (20.7) | (15.8) | — | — |
| Income Tax Expense | — | 3.4 | — | 0.0 | 0.0 | 0.0 | (0.1) | 0.1 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||
| Net Income | — | (183.4) | (126.6) | (92.9) | (82.3) | (46.2) | (29.1) | (20.8) | (15.8) | (18.6) | (24.8) |
| Per Share | |||||||||||
| Basic EPS | — | (3.69) | (3.44) | (3.33) | (3.36) | (2.42) | (1.64) | — | — | — | — |
| Diluted EPS | — | (3.69) | (3.44) | (3.33) | (3.36) | (2.42) | (1.64) | — | — | — | — |
| Basic Weighted Avg Shares | 54.6 | 49.7 | 36.8 | 27.9 | 24.5 | 19.1 | 17.7 | — | — | — | — |
| Diluted Weighted Avg Shares | 54.6 | 49.7 | 36.8 | 27.9 | 24.5 | 19.1 | 17.7 | — | — | — | — |
| Supplemental | |||||||||||
| EBITDA | — | (187.1) | (139.6) | (110.2) | (96.0) | (57.4) | (40.0) | (29.4) | (18.5) | (22.3) | (20.9) |
| EBIT | — | (188.0) | (140.4) | (110.9) | (96.6) | (57.9) | (40.5) | (29.8) | (18.7) | (22.3) | (21.0) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.4% | -0.6% | 0.0% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.